Specialisation and breast cancer survival in the screening era
2003

Specialisation and Breast Cancer Survival

Sample size: 7673 publication Evidence: high

Author Information

Author(s): D. Kingsmore, A. Ssemwogerere, D. Hole, C. Gillis

Primary Institution: University of Glasgow

Hypothesis

Does the survival advantage associated with specialist treatment of breast cancer persist after the introduction of screening?

Conclusion

The survival advantage associated with specialist treatment has persisted with longer-term follow-up and is also apparent in the postscreening cohort of women.

Supporting Evidence

  • The percentage of women treated by specialists increased from 11% to 59% over the study period.
  • 5-year survival improved from 60% in the prescreening era to 73% in the postscreening era.
  • Specialist treatment showed a relative hazard ratio of 0.83 in the prescreening era and 0.89 in the postscreening era.

Takeaway

This study found that women treated by specialist surgeons for breast cancer tend to live longer, even after screening programs were introduced.

Methodology

The study analyzed survival patterns of women with invasive breast cancer diagnosed between 1980 and 1994, comparing treatment outcomes between specialist and nonspecialist surgeons.

Potential Biases

Potential biases include lead-time and length-time biases due to differences in tumor detection methods.

Limitations

The definition of 'specialisation' was subjective and based on local surgeons' opinions, which may not be universally applicable.

Participant Demographics

Women aged under 75 years with histologically proven invasive breast cancer.

Statistical Information

P-Value

p<0.001

Confidence Interval

95% CI=0.53–0.62

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1038/sj.bjc.6600949

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication